SLC ELISA Kits are designed for the quantitative measurement of solute carrier (SLC) proteins in various biological samples. SLC proteins are a diverse group of membrane transporters that play critical roles in the transport of a wide range of molecules across cellular membranes.
Technical Content
Key Features:
- High Sensitivity: Capable of detecting low concentrations of SLC proteins, ensuring precise quantification in samples.
- Specificity: High specificity for target SLC proteins, minimizing cross-reactivity with other proteins.
- Broad Applicability: Suitable for use with serum, plasma, cell lysates, and other biological fluids.
Applications:
- Molecular Biology: Used to study the expression and regulation of SLC transporters in different tissues and under various conditions.
- Clinical Research: Assists in investigating the role of SLC proteins in diseases such as metabolic disorders, neurological diseases, and cancers.
- Drug Development: Facilitates the evaluation of drug effects on SLC transporter activity and expression.
Usage Protocol:
- Sample Preparation: Collect and prepare samples according to the kit's instructions. Dilute if necessary.
- Assay Procedure: Add samples, standards, and controls to the wells of the ELISA plate pre-coated with antibodies specific to the target SLC protein.
- Incubation: Incubate the plate to allow binding of the SLC proteins to the antibodies.
- Detection: Add detection antibodies and enzyme substrate to produce a colorimetric signal proportional to the SLC protein concentration.
- Analysis: Measure the absorbance using a microplate reader and calculate SLC protein concentrations based on the standard curve.
Benefits:
- Precision: Provides reliable and reproducible results for the accurate quantification of SLC proteins.
- Efficiency: Simplified protocol with ready-to-use reagents reduces assay time and labor.
- Versatility: Compatible with a variety of sample types, making it suitable for diverse research applications.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|